Cofoe Medical Technology Co., Ltd.
可孚醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1187)

2026 FIRST QUARTERLY REPORT

The financial data contained in this quarterly report is unaudited and has been prepared in accordance with the China Accounting Standards for Business Enterprises.

IMPORTANT NOTICE:

The Board of Directors of the Company, as well as its directors and senior management, warrant that the contents of this quarterly report are true, accurate, and complete, and contain no false records, misleading statements, or material omissions, and they assume individual and joint legal liability for its contents.

The person in charge of the Company, the person in charge of accounting affairs, and the head of the accounting department (accounting supervisor) warrant the truth, accuracy, and completeness of the financial information in this quarterly report.

Whether the Q1 financial statements have been audited

☐ Yes ☑ No

I. KEY FINANCIAL DATA

(I) Key Accounting Data and Financial Indicators

Does the Company need to retrospectively adjust or restate the accounting data of previous years?

☐ Yes ☑ No

Unit: RMB

	The reporting period	Same period of last year	Increase/decrease in the reporting period compared to the same period of previous year (%)
Operating revenue	1,012,368,240.57	737,792,254.37	37.22%
Net profit attributable to shareholders of the listed company	107,041,703.68	91,425,130.39	17.08%
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss	93,790,509.89	68,522,530.19	36.88%
Net cash flows from operating activities	102,560,132.89	110,058,277.19	-6.81%
Basic earnings per share (RMB/share)	0.52	0.45	15.56%
Diluted earnings per share (RMB/share)	0.51	0.44	15.91%
Weighted average return on net assets	2.18%	1.89%	Increased by 0.29 percentage points

	End of the reporting period	End of last year	Increase/decrease at the end of the reporting period compared to the end of last year (%)
Total assets	6,913,387,005.28	6,628,915,230.03	4.29%
Owners' equity attributable to shareholders of the listed company	4,731,839,687.12	4,866,857,736.11	-2.77%

(II) Non-recurring Profit or Loss Items and Amounts

☑ Applicable ☐ Not applicable

Unit: RMB

Item	Amount for the reporting period	Description
Profit or loss on disposal of non-current assets (including the write-off of the provision for impairment of assets)	36,578.59	
Government grants recognized in current profit or loss (except for those closely related to the Company's normal business operations, in line with national policies, enjoyed according to established standards, and having a continuous impact on the Company's profit or loss)	9,968,218.05	
Profit or loss from changes in fair value of financial assets and financial liabilities held by non-financial enterprises, and profit or loss from the disposal of financial assets and financial liabilities, except for effective hedging activities related to the Company's normal business operations	5,189,505.72	
Other non-operating income and expenses excluding the above items	402,184.38	
Less: Income tax effect	2,413,151.65	
Effect of non-controlling interests (after tax)	-67,858.70	
Total	13,251,193.79	–

Details of other profit or loss items that meet the definition of non-recurring profit or loss

☐ Applicable ☑ Not applicable

The Company does not have other profit or loss items that meet the definition of non-recurring profit or loss.

Explanation for defining non-recurring profit or loss items listed in the *Explanatory Announcement No.1 on Information Disclosure for Companies Publicly Issuing Securities – Non-recurring Profit or Loss* as recurring profit or loss items

☐ Applicable ☑ Not applicable

The Company does not have any circumstances where non-recurring profit or loss items listed in the *Explanatory Announcement No.1 on Information Disclosure for Companies Publicly Issuing Securities – Non-recurring Profit or Loss* are defined as recurring profit or loss items.

(III) Changes in Major Accounting Data and Financial Indicators and the Reasons

☑ Applicable ☐ Not applicable

1. *Changes in the Consolidated Balance Sheet and the reasons*

Unit: RMB

Item	March 31, 2026	December 31, 2025	Percentage of change	Reason
Prepayments	221,382,446.45	147,847,688.07	49.74%	Mainly due to the increase in prepayments for goods to suppliers during the current period
Short-term borrowings	911,606,526.17	574,747,853.12	58.61%	Mainly due to the increase in short-term unsecured bank borrowings during the current period
Employee benefits payable	39,666,333.69	58,473,078.53	-32.16%	Mainly due to the payment of the annual performance compensation of the prior period in the current period, resulting in decreased balance of employee benefits payable
Taxes and surcharges payable	43,301,597.96	19,926,312.94	117.31%	Mainly due to the increase in VAT payable during the current period
Other payables	301,670,607.95	70,335,081.89	328.90%	Mainly due to the increase in dividends declared but not yet paid during the current period
Non-current liabilities due within one year	43,725,631.48	183,395,494.54	-76.16%	Mainly due to the repayment of long-term bank borrowings outstanding at the beginning of the period
Accumulated other comprehensive income	-4,045,183.27	-1,548,497.70	-161.23%	Mainly due to an increase in the foreign currency translation difference for the current period

2. *Changes in the Consolidated Income Statement and the reasons*

Unit: RMB

Item	Amount for the current period	Amount for the prior period	Percentage of change	Reason
Operating revenue	1,012,368,240.57	737,792,254.37	37.22%	Mainly due to the overall revenue growth driven by a substantial sales increase in the core medical and healthcare category, tiered growth across multiple categories, and robust development of online channels
Taxes and surcharges	10,478,524.57	7,186,093.72	45.82%	Mainly due to the increase in city maintenance and construction tax and education surcharges during the current period
Selling expenses	352,910,826.12	228,420,929.02	54.50%	Mainly due to the expansion of online business scale and increased marketing spending in the current period, which pushed up e-commerce-related expenses, as well as the inclusion of selling expenses of subsidiaries acquired at mid-year of the prior period within the consolidation scope
Finance expenses	1,575,761.90	-1,605,979.89	198.12%	Mainly due to the increase in exchange losses during the current period
Other income	15,136,311.84	27,279,599.78	-44.51%	Mainly due to the decrease in income related to government grants during the current period
Investment income	-2,733,668.78	10,327,107.82	-126.47%	Mainly due to the gain on disposal of a subsidiary in the prior period, whereas there was no such gain in the current period

Item	Amount for the current period	Amount for the prior period	Percentage of change	Reason
Credit impairment losses	92,367.59	-2,210,612.65	104.18%	Mainly due to the reversal of provision for bad debts on other receivables in the current period
Impairment losses of assets	-16,363,970.50	-24,570,225.42	33.40%	Mainly due to the decrease in the provision for inventory impairment recognized during the current period
Non-operating income	1,100,599.72	799,959.72	37.58%	Mainly due to the increase in compensation and indemnities received in the current period
Non-controlling interest profit or loss	370,055.31	147,728.77	150.50%	Mainly due to the increase in profit or loss attributable to non-controlling interests of the companies acquired during the current period

3. *Changes in the Consolidated Cash Flow Statement and the reasons*

Unit: RMB

Item	Amount for the current period	Amount for the prior period	Percentage of change	Reason
Net cash flows from investing activities	-190,902,172.37	-94,905,406.71	-101.15%	Mainly due to the maturity of wealth management products purchased in the previous period
Net cash flows from financing activities	189,968,785.26	-104,280,370.94	282.17%	Mainly due to the increase in bank loans obtained in the current period
Effect of exchange rate changes on cash and cash equivalents	-3,225,998.04	-1,034.91	-311617.74%	Mainly due to exchange rate fluctuations

II. SHAREHOLDER INFORMATION

(I) Table of Total Number of Ordinary Shareholders, the Number of Preferred Shareholders with Restored Voting Rights, and the Shareholdings of the Top 10 Shareholders

Unit: share

Total number of ordinary shareholders at the end of the reporting period	**16,386**	**Total number of preferred shareholders with restored voting rights at the end of the reporting period (if any)**	**0**

Shareholdings of the top 10 shareholders (excluding shares lent through securities refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage (%)	Number of shares held	Number of shares held with selling restrictions	Pledge, marking, or freezing status	
					Share status	Quantity
Changsha Xiezihao Medical Investment Co., Ltd.	Domestic non-state-owned legal person	40.73%	85,079,923	0	Not applicable	0
Zhang Min	Domestic natural person	5.80%	12,114,881	9,086,161	Not applicable	0
Changsha Keyuan Tongchuang Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	5.80%	12,114,881	0	Not applicable	0
Zhang Zhiming	Domestic natural person	3.48%	7,268,928	5,451,696	Not applicable	0
Huagai Capital Co., Ltd. – Capital Healthcare Industry (Beijing) Fund (Limited Partnership)	Others	2.00%	4,181,840	0	Not applicable	0
Ningbo Huaige Health Investment Management Partnership (Limited Partnership) – Ningbo Huaige Gongxin Venture Capital Partnership (Limited Partnership)	Others	1.91%	4,000,000	0	Not applicable	0
Nie Juan	Domestic natural person	1.67%	3,485,739	0	Not applicable	0
Vision Capital Management Co., Ltd. – Vision China Value Growth No. 16 Private Equity Investment Fund	Others	0.89%	1,850,090	0	Not applicable	0
Bank of Communications Co., Ltd. – Cathay Golden Eagle Growth Flexible Allocation Mixed Securities Investment Fund	Others	0.80%	1,668,631	0	Not applicable	0
Basic Pension Insurance Fund Portfolio 2101	Others	0.76%	1,589,165	0	Not applicable	0

Shareholdings of the top 10 shareholders of shares without selling restrictions (excluding shares lent through refinancing and senior management's locked-in shares)

Name of shareholder	Number of shares held without selling restrictions	Type of shares: Type of shares	Type of shares: Quantity
Changsha Xiezihao Medical Investment Co., Ltd.	85,079,923	RMB common shares	85,079,923
Changsha Keyuan Tongchuang Enterprise Management Center (Limited Partnership)	12,114,881	RMB common shares	12,114,881
Huagai Capital Co., Ltd. – Capital Healthcare Industry (Beijing) Fund (Limited Partnership)	4,181,840	RMB common shares	4,181,840
Ningbo Huaige Health Investment Management Partnership (Limited Partnership) – Ningbo Huaige Gongxin Venture Capital Partnership (Limited Partnership)	4,000,000	RMB common shares	4,000,000
Nie Juan	3,485,739	RMB common shares	3,485,739
Zhang Min	3,028,720	RMB common shares	3,028,720
Vision Capital Management Co., Ltd. – Vision China Value Growth No. 16 Private Equity Investment Fund	1,850,090	RMB common shares	1,850,090
Zhang Zhiming	1,817,232	RMB common shares	1,817,232
Bank of Communications Co., Ltd. – Cathay Golden Eagle Growth Flexible Allocation Mixed Securities Investment Fund	1,668,631	RMB common shares	1,668,631
Basic Pension Insurance Fund Portfolio 2101	1,589,165	RMB common shares	1,589,165
Explanation of the related-party relationship or acting-in-concert relationship among the above shareholders	1. Zhang Min and Nie Juan are husband and wife and are the actual controllers of the Company. 2. Zhang Min and Nie Juan collectively hold 100% of the equity of Xiezihao Medical Investment, Zhang Min is the executive director of Xiezihao Medical Investment, and Nie Juan is the general manager of Xiezihao Medical Investment. 3. Zhang Min is the general partner and executive partner of Keyuan Tongchuang, holding 5% of the capital contribution. Nie Juan is a limited partner of Keyuan Tongchuang, holding 55% of the capital contribution. Zhang Zhiming is a limited partner of Keyuan Tongchuang, holding 40% of the capital contribution. 4. Apart from the above, the Company is not aware of whether there is any related-party relationship among the other top 10 shareholders.		
Explanation of the participation of the top 10 shareholders in margin trading and securities lending (if any)	The shareholder, Vision Capital Management Co., Ltd. (遠信(珠海)私募基金管理有限公司) – Vision China Value Growth No.16 Private Equity Investment Fund, holds 1,150,000 Shares of the Company via a general securities account and 700,090 Shares of the Company via a margin trading collateral securities account, with an actual aggregate holding of 1,850,090 Shares of the Company.		

Note: At the end of the reporting period, the Company has a special repurchase account—"Special Repurchase Securities Account of Cofoe Medical Technology Co., Ltd." (listed as the 7th shareholder in the register, but not included in the list of the top 10 shareholders). This repurchase account holds 3,878,731 shares of the Company, accounting for 1.86% of the total share capital.

Participation of shareholders holding more than 5% of shares, the top 10 shareholders, and the top 10 shareholders of tradable shares without selling restrictions in share lending through refinancing

☐ Applicable ☑ Not applicable

Changes in the top 10 shareholders and the top 10 shareholders of tradable shares without selling restrictions compared with the previous period due to lending/return of shares through refinancing

☐ Applicable ☑ Not applicable

(II) Total Number of Preferred Shareholders and Shareholdings of the Top 10 Preferred Shareholders

☐ Applicable ☑ Not applicable

(III) Changes in Shares Subject to Selling Restrictions

☐ Applicable ☑ Not applicable

III. OTHER SIGNIFICANT EVENTS

☑ Applicable ☐ Not applicable

The Company is currently in the process of the relevant work of applying for the issuance of overseas listed foreign shares (H Shares) and listing on the Main Board of The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Hong Kong Stock Exchange"). On March 6, 2026, the Company received the "Notice on Filing for the Overseas Issuance and Listing of Cofoe Medical Technology Co., Ltd." (GHH [2026] No. 499) issued by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"). The CSRC confirmed the filing information for the Company's current issuance and listing. On March 16, 2026, the Company submitted an updated application for the current issuance to the Hong Kong Stock Exchange and published the updated application materials for the current issuance on the website of the Hong Kong Stock Exchange on the same day. On March 26, 2026, the Listing Committee of the Hong Kong Stock Exchange held a listing hearing to deliberate on the Company's application for the current issuance and listing. The Joint Sponsors for the Company's current issuance and listing received a letter from the Hong Kong Stock Exchange on March 27, 2026, stating that the Listing Committee of the Hong Kong Stock Exchange has reviewed the Company's listing application, but the letter does not constitute a formal listing approval, and the Hong Kong Stock Exchange still reserves the right to raise further comments on the Company's listing application. For further details, please refer to the relevant announcements disclosed by the Company on CNINFO (www.cninfo.com.cn).

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statements

1. Consolidated Balance Sheet

Prepared by: Cofoe Medical Technology Co., Ltd.

March 31, 2026

Unit: RMB

Item	March 31, 2026	December 31, 2025
Current assets:		
Currency funds	1,492,533,526.14	1,421,698,948.31
Settlement reserves		
Placements with banks and other financial institutions		
Financial assets held for trading	1,178,051,156.53	1,016,829,270.02
Derivative financial assets		
Notes receivable	13,927,274.75	14,955,203.08
Accounts receivable	428,521,215.66	404,787,366.02
Receivables financing	18,080,281.19	25,043,014.05
Prepayments	221,382,446.45	147,847,688.07
Premiums receivable		
Reinsurance receivables		
Reinsurance contract reserves receivable		
Other receivables	66,620,233.65	59,091,364.80
Including: Interest receivable		
Dividends receivable		
Financial assets purchased under agreements to sell		
Inventories	676,862,102.93	675,498,725.47
Including: Data resource		
Contract assets		
Assets held for sale		
Non-current assets due within one year	2,213,578.09	2,273,687.62
Other current assets	65,796,202.45	67,296,397.04
Total current assets	4,163,988,017.84	3,835,321,664.48

Item	March 31, 2026	December 31, 2025
Non-current assets:		
Loans and advances		
Debt investments		
Other debt investments		
Long-term receivables	4,630,081.33	4,932,150.22
Long-term equity investments	234,543,727.62	237,335,163.60
Other investments in equity instruments		
Other non-current financial assets	5,961,500.00	5,961,500.00
Investment properties	27,147,103.31	27,962,154.04
Fixed assets	1,453,876,926.29	1,480,098,923.28
Construction in progress	140,959,019.90	138,628,836.57
Productive biological assets		
Oil & gas assets		
Right-of-use assets	117,438,859.80	131,585,717.77
Intangible assets	275,696,922.27	278,125,879.79
Including: Data resource		
Development expenditures	18,838,932.51	17,256,536.34
Including: Data resource		
Goodwill	368,912,266.63	368,912,266.63
Long-term prepaid expenses	42,578,756.84	46,255,941.89
Deferred income tax assets	41,344,762.25	40,525,069.53
Other non-current assets	17,470,128.69	16,013,425.89
Total non-current assets	2,749,398,987.44	2,793,593,565.55
Total assets	6,913,387,005.28	6,628,915,230.03

Item	March 31, 2026	December 31, 2025
Current liabilities:		
Short-term borrowings	911,606,526.17	574,747,853.12
Borrowings from the Central Bank		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable	100,548,423.48	80,408,238.55
Accounts payable	522,163,200.92	558,637,328.21
Receipts in advance	275,803.35	233,538.80
Contract liabilities	33,276,393.28	29,073,453.36
Financial assets sold for repurchase		
Receipt of deposits and deposits from other banks		
Deposit for securities trading brokerage		
Deposit for securities underwriting brokerage		
Employee benefits payable	39,666,333.69	58,473,078.53
Taxes and surcharges payable	43,301,597.96	19,926,312.94
Other payables	301,670,607.95	70,335,081.89
Including: Interest payable		
Dividends payable	246,021,922.80	
Fees and commissions payable		
Reinsurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	43,725,631.48	183,395,494.54
Other current liabilities	13,807,809.04	13,535,462.57
Total current liabilities	2,010,042,327.32	1,588,765,842.51

Item	March 31, 2026	December 31, 2025
Non-current liabilities:		
Insurance contract reserves		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	65,736,460.36	68,036,539.67
Long-term payables		
Long-term employee benefits payable	2,817,264.74	2,881,777.87
Provisions		
Deferred income	59,503,532.89	58,592,909.47
Deferred tax liabilities	7,384,697.21	7,749,673.09
Other non-current liabilities		
Total non-current liabilities	135,441,955.20	137,260,900.10
Total liabilities	2,145,484,282.52	1,726,026,742.61
Owners' equity:		
Share capital	208,897,000.00	208,897,000.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserves	3,932,148,251.14	3,925,689,395.44
Less: Treasury shares	140,471,434.28	140,471,434.28
Accumulated other comprehensive income	-4,045,183.27	-1,548,497.70
Specialised reserves		
Surplus reserve	104,546,000.00	104,546,000.00
General risk provision		
Unappropriated profit	630,765,053.53	769,745,272.65
Total owners' equity attributable to equity holders of the parent	4,731,839,687.12	4,866,857,736.11
Non-controlling interests	36,063,035.64	36,030,751.31
Total owners' equity	4,767,902,722.76	4,902,888,487.42
Total liabilities and owners' equity	6,913,387,005.28	6,628,915,230.03

Legal Representative:	*Person in Charge of Accounting Affairs:*	*Head of Accounting Department:*
ZHANG Min	**CHEN Wangpeng**	**SHEN Pei**

2. Consolidated Income Statement

Prepared by: Cofoe Medical Technology Co., Ltd.

Unit: RMB

Item	Amount for the current period (January-March 2026)	Amount for the prior period (January-March 2025)
I. Total operating revenue	1,012,368,240.57	737,792,254.37
Including: Operating revenue	1,012,368,240.57	737,792,254.37
Interest income		
Insurance premiums earned		
Handling fees and commission income		
II. Total operating costs	885,037,584.77	646,327,861.69
Including: Operating costs	454,005,528.45	352,894,626.27
Interest expenses		
Handling fees and commission expenses		
Surrender value		
Net claims paid		
Net amount of insurance reserves provided		
Insurance policy dividend paid		
Reinsurance expenses		
Taxes and surcharges	10,478,524.57	7,186,093.72
Selling expenses	352,910,826.12	228,420,929.02
Administrative expenses	43,977,336.58	40,596,125.82
Research and development expenses	22,089,607.15	18,836,066.75
Finance expenses	1,575,761.90	-1,605,979.89
Including: Interest expenses	2,895,462.23	2,867,033.16
Interest income	6,175,523.59	5,903,846.90
Add: Other income	15,136,311.84	27,279,599.78
Investment income (loss shall be stated as "-")	-2,733,668.78	10,327,107.82
Including: Income from investments in associates and joint ventures	-2,791,435.98	277,173.14
Gains on derecognition of financial assets measured at amortized cost		
Foreign exchange gain (loss shall be stated as "-")		
Net gain on exposure hedging (loss shall be stated as "-")		
Fair value gains (loss shall be stated as "-")	5,131,738.53	7,290,001.24
Credit impairment losses (loss shall be stated as "-")	92,367.59	-2,210,612.65
Impairment losses of assets (loss shall be stated as "-")	-16,363,970.50	-24,570,225.42

Item	Amount for the current period (January-March 2026)	Amount for the prior period (January-March 2025)
Gains on disposal of non-current assets (loss shall be stated as "-")	72,734.00	87,558.44
III. Operating profit (loss shall be stated as "-")	128,666,168.48	109,667,821.89
Add: Non-operating income	1,100,599.72	799,959.72
Less: Non-operating expenses	734,570.75	1,041,080.34
IV. Total profit (total loss shall be stated as "-")	129,032,197.45	109,426,701.27
Less: Income tax expenses	21,620,438.46	17,853,842.11
V. Net profit (net loss shall be stated as "-")	107,411,758.99	91,572,859.16
(I) Classified by continuity of operations		
1. Net profit from continuing operations (net loss shall be stated as "-")	107,411,758.99	91,572,859.16
2. Net profit from discontinued operations (net loss shall be stated as "-")		
(II) By ownership of the equity		
1. Net profit attributable to owners of the parent	107,041,703.68	91,425,130.39
2. Non-controlling interest profit or loss	370,055.31	147,728.77
VI. Other comprehensive income, net of tax	-2,847,497.23	
Other comprehensive income attributable to the owners of the parent, net of tax	-2,496,685.57	
(I) Other comprehensive income that may not be reclassified to profit or loss		
1. Changes arising from remeasurement under defined benefit plan		
2. Other comprehensive income that may not be transferred to profit or loss under equity method		
3. Change in fair value of investments in other equity instruments		
4. Change in fair value of the Company's own credit risk		
5. Others		

Item	Amount for the current period (January-March 2026)	Amount for the prior period (January-March 2025)
(II) Other comprehensive income that may be reclassified to profit or loss	-2,496,685.57	
1. Other comprehensive income that may be reclassified to profit or loss under equity method		
2. Change in fair value of other debt investments		
3. Amount of financial asset reclassification included in other comprehensive income		
4. Credit impairment allowance of other debt investments		
5. Cash flow hedging reserve		
6. Exchange differences on translation of foreign currency financial statements	-2,496,685.57	
7. Others		
Other comprehensive income, net of tax, attributable to non-controlling interests	-350,811.66	
VII. Total comprehensive income	104,564,261.76	91,572,859.16
Total comprehensive income attributable to the owners of the parent	104,545,018.11	91,425,130.39
Total comprehensive income attributable to non-controlling interests	19,243.65	147,728.77
VIII. Earnings per share:		
(I) Basic earnings per share	0.52	0.45
(II) Diluted earnings per share	0.51	0.44

Legal Representative:	*Person in Charge of Accounting Affairs:*	*Head of Accounting Department:*
ZHANG Min	**CHEN Wangpeng**	**SHEN Pei**

3. Consolidated Cash Flow Statement

Prepared by: Cofoe Medical Technology Co., Ltd.

Unit: RMB

Item	Amount for the current period (January-March 2026)	Amount for the prior period (January-March 2025)
I. Cash flows from operating activities:		
Cash received from sales of goods or rendering of services	1,030,430,502.74	748,166,889.53
Net increase in customer deposits and placements from banks and other financial institutions		
Net increase in borrowings from the Central Bank		
Net increase in borrowings from other financial institutions		
Cash received from premiums of original insurance contracts		
Net cash received from reinsurance business		
Net increase in policyholders' deposits and investment funds		
Cash received from interest, handling fees, and commissions		
Net increase in borrowings from banks and other financial institutions		
Net increase in funds from repurchase agreements		
Net cash received from securities brokerage		
Refunds of taxes and surcharges	8,862,595.69	2,065,452.90
Other cash received relating to operating activities	78,560,994.31	41,644,476.87
Subtotal of cash inflows from operating activities	1,117,854,092.74	791,876,819.30
Cash paid for purchasing goods and receiving services	439,847,845.67	300,408,389.36
Net increase in loans and advances to customers		
Net increase in deposits with the Central Bank and placements with banks and other financial institutions		
Cash paid for claims under original insurance contracts		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, handling fees, and commissions		

Item		Amount for the current period (January-March 2026)	Amount for the prior period (January-March 2025)
	Cash paid for policy dividends		
	Cash paid to and on behalf of employees	174,014,836.43	164,952,962.00
	Payments of taxes and surcharges	44,792,571.17	48,986,718.44
	Other cash paid relating to operating activities	356,638,706.58	167,470,472.31
	Subtotal of cash outflows from operating activities	1,015,293,959.85	681,818,542.11
	Net cash flows from operating activities	102,560,132.89	110,058,277.19
II.	**Cash flows from investing activities:**		
	Cash received from disposal of investments	150,110,000.00	62,767,847.81
	Cash received from returns on investments	1,857,619.22	17,013.89
	Net cash received from disposals of fixed assets, intangible assets and other long-term assets	19,283.21	5,913,933.43
	Net cash receipts from the disposal of subsidiaries and other business units		
	Other cash received relating to investing activities		
	Subtotal of cash inflows from investing activities	151,986,902.43	68,698,795.13
	Cash paid to acquire fixed assets, intangible assets and other long-term assets	33,529,360.49	68,909,262.74
	Cash paid to acquire investments	309,359,714.31	85,675,069.00
	Net increase in pledged loans		
	Net cash paid to acquire subsidiaries and other business units		8,781,956.32
	Other cash paid relating to investing activities		237,913.78
	Subtotal of cash outflows from investing activities	342,889,074.80	163,604,201.84
	Net cash flows from investing activities	-190,902,172.37	-94,905,406.71

Item		Amount for the current period (January-March 2026)	Amount for the prior period (January-March 2025)
III.	**Cash flows from financing activities:**		
	Cash received from capital contributions		700,000.00
	Including: Cash received by subsidiaries from minority shareholders' investment		700,000.00
	Cash received from borrowings	667,044,378.36	383,094,199.19
	Other cash received relating to financing activities		55,291,458.11
	Subtotal of cash inflows from financing activities	667,044,378.36	439,085,657.30
	Cash paid for repayment of debts	457,359,945.50	484,876,312.10
	Cash paid for distribution of dividends or profits and for interest expenses	1,152,506.76	1,771,532.25
	Including: Dividends or profits paid by subsidiaries to minority shareholders		
	Other cash paid relating to financing activities	18,563,140.84	56,718,183.89
	Subtotal of cash outflows from financing activities	477,075,593.10	543,366,028.24
	Net cash flows from financing activities	189,968,785.26	-104,280,370.94
IV.	**Effect of foreign exchange rate changes on cash and cash equivalents**	-3,225,998.04	-1,034.91
V.	**Net increase in cash and cash equivalents**	98,400,747.74	-89,128,535.37
	Add: Cash and cash equivalents at the beginning of the reporting period	1,294,575,300.70	1,139,986,138.54
VI.	**Cash and cash equivalents at the end of the reporting period**	1,392,976,048.44	1,050,857,603.17

Legal Representative:	*Person in Charge of Accounting Affairs:*	*Head of Accounting Department:*
ZHANG Min	**CHEN Wangpeng**	**SHEN Pei**

(II) Adjustments to Relevant Items of the Financial Statements at the Beginning of the Year of First-Time Adoption of New Accounting Standards from 2026

☐ Applicable ☑ Not applicable

(III) Audit Report

Whether the Q1 financial report has been audited

☐ Yes ☑ No

The Q1 financial report of the Company has not been audited.

This announcement is hereby made.

By order of the Board
Cofoe Medical Technology Co., Ltd.
Mr. ZHANG Min
Executive Director and Chairman of the Board

Changsha, the PRC, April 29, 2026

The directors of the Company named in the application to which this announcement relates are: (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive directors.

This report is prepared in both Chinese and English languages. In the event of any inconsistency between these two versions, the Chinese version shall prevail.